Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16376659 | 0.78 | CYP2C19 (0.47) | KDM4EHSD17B10HPGDGABRA1GABRB2 | |
| SCHEMBL9390060 | 0.77 | CHRM2 (0.40) | KDM4EHSD17B10ALDH1A1HPGDGABRA1 | |
| SCHEMBL9374719 | 0.72 | SIGMAR1 (0.44) | KDM4EHSD17B10ALDH1A1HPGDGABRA1 | |
| SCHEMBL3356438 | 0.71 | HPGD (0.43) | HPGDGABRA1GABRB2CHRM2CHRM4 | |
| SCHEMBL27532834 | 0.70 | CYP3A4 (0.49) | GABRA1GABRB2MAOBARCYP19A1 | |
| SCHEMBL30633819 | 0.70 | GABRA1 (0.53) | GABRA1GABRB2MAOBARCYP19A1 | |
| SCHEMBL403523 | 0.70 | MAOB (0.65) | KDM4EHSD17B10ALDH1A1HPGDMAOB | |
| SCHEMBL32498549 | 0.70 | MAOB (0.65) | KDM4EHSD17B10ALDH1A1HPGDMAOB | |
| SCHEMBL23867147 | 0.69 | HSP90AB1 (0.44) | KDM4EHSD17B10ALDH1A1HPGDGABRA1 | |
| SCHEMBL11044983 | 0.69 | HSP90AB1 (0.44) | KDM4EHSD17B10ALDH1A1HPGDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2021117016-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. (IL) | 2021-06-17 | — | — | WO | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200093851-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| US-20170246201-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170151269-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151268-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20150150770-A1 | METHODS OF TREATING SKIN | TRACIE MARTYN INTERNATIONAL INC (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140155961-A1 | METHODS OF TREATING SKIN | Tracie Martyn International, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20100272790-A1 | Methods of Treating Skin | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7776915-B2 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20060216251-A1 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155961-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | KDM4E 1602/4885HSD17B10 583/4885ALDH1A1 920/4885 |
| US-20100272790-A1 | Methods of Treating Skin | CUTA, LIPA, DLAT | KDM4E 1602/4885HSD17B10 583/4885ALDH1A1 920/4885 |
| US-20150150770-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | KDM4E 1602/4885HSD17B10 583/4885ALDH1A1 920/4885 |
| US-20060216251-A1 | Topical formulations and methods of use | CPT1B, SLC25A20, CPT1A | KDM4E 2265/4885HSD17B10 512/4885ALDH1A1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.